Melbourne-based therapeutic antibody development company Patrys (ASX:PAB) has announced the appointment of US-based biotechnology executive, Dr Peter Ordentlich, to its Scientific Advisory Board (SAB).
Dr Ordentlich completed a PhD in Immunology at the University of Pennsylvania and a Post-Doc at the Salk Institute for Biological Studies before joining X-Ceptor Therapeutics, a discovery stage biotechnology company focused on the identification of novel therapeutics for cardiovascular and oncology indications.
Dr Ordentlich spent five years as a research scientist, leading multiple lead discovery and optimisation projects at X-Ceptor Therapeutics, which was acquired by Exelixis in 2004.
In 2005, Dr Ordentlich co-founded Syndax Pharmaceuticals, a NASDAQ-listed, clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies with three clinical-stage assets. He is currently the chief scientific officer.
“Peter has built a strong portfolio of skills in translational medicine and clinical development over the course of his career,” said Patrys CEO and managing director, Dr James Campbell.
“As Patrys moves towards an anticipated phase 1 study of PAT-DX1 in the second half of next year we are very fortunate to access the expertise of our world-class SAB, which has progressed tens of molecules, both biologics and small molecules, into the clinic. On behalf of Patrys I would like to warmly welcome Peter to our team – he, together with Dr Allen Ebens and Dr Pamela M. Klein, will offer invaluable expertise and advice as we progress through this pivotal stage for the Company.”